GKOS Stock Analysis: Glaukos | NYSE
Medical Devices | NYSE, USA | Market Cap: 10.701m USD | 12M Return: 214.5% | US3773221029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 169M
Qual. Beats: 1
Rev. Trend: 98.9%
Qual. Beats: 10
Warnings
Tailwinds
Seasonality 11.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company that develops therapies for glaucoma, corneal disorders, and retinal diseases, operating in the United States and internationally. The company is classified within the GICS Health Care Equipment sub-industry and sits in the mid-cap segment of the U.S. equity market.
Its commercial portfolio centers on the iStent family of micro-bypass stents, including iStent inject W for mild-to-moderate open-angle glaucoma and iStent infinite for patients uncontrolled by prior therapy, alongside iDose TR, an intracameral procedural pharmaceutical designed to lower intraocular pressure. The company also develops pipeline products such as iLink for keratoconus, ILution for transdermal delivery to the eyelid surface, and a retinal XR platform targeting age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Glaukos sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was incorporated in 1998, originally as Transdx, Inc., and is headquartered in Aliso Viejo, California, having gone public in 2015.
- iDose TR launch drives glaucoma pharmaceutical revenue growth
- iStent infinite adoption expands surgical glaucoma market share
- Retinal XR pipeline progress unlocks AMD and DME markets
- Keratoconus iLink approval addresses corneal disorder opportunity
- Reimbursement and ASC coverage decisions impact procedure volumes
| Net Income: -169.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 6.44 > 1.0 |
| NWC/Revenue: 65.61% < 20% (prev 78.17%; Δ -12.56% < -1%) |
| CFO/TA 0.05 > 3% & CFO 47.7m > Net Income -169.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.2m) vs 12m ago 6.62% < -2% |
| Gross Margin: 81.13% > 18% (prev 76.87%; Δ 4.26% > 0.5%) |
| Asset Turnover: 69.77% > 50% (prev 47.01%; Δ 22.76% > 0%) |
| Interest Coverage Ratio: -35.13 > 6 (EBIT TTM -169.2m / Interest Expense TTM 4.82m) |
| A: 0.46 (Total Current Assets 579.6m - Total Current Liabilities 126.7m) / Total Assets 979.5m |
| B: -0.99 (Retained Earnings -969.3m / Total Assets 979.5m) |
| C: -0.17 (EBIT TTM -169.2m / Avg Total Assets 989.5m) |
| D: 2.74 (Book Value of Equity 717.3m / Total Liabilities 262.3m) |
| Altman-Z'' = 1.53 = BB |
| DSRI: 1.03 (Receivables 150.0m/98.7m, Revenue 690.3m/469.8m) |
| GMI: 0.95 (GM 76.87% / 81.13%) |
| AQI: 0.62 (AQ_t 0.22 / AQ_t-1 0.36) |
| SGI: 1.47 (Revenue 690.3m / 469.8m) |
| TATA: -0.22 (NI -169.8m - CFO 47.7m) / TA 979.5m) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of October 30, 2026, the stock is trading at USD 242.48 with a total of 5,415,630 shares traded. Over the past week, the price has changed by +37.23%, over one month by +52.94%, over three months by +49.99% and over the past year by +214.54%.
Current recommended Stop Loss: 234.00 (which is 3.5% or 1.2 ATR below the current price).
Glaukos has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy GKOS.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 199.3 | -17.8% |
P/E Forward = 1666.6667
P/S = 17.4621
P/B = 15.6576
P/EG = 1.64
Revenue TTM = 690.3m USD
EBIT TTM = -169.2m USD
EBITDA TTM = -122.9m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 102.0m USD (from shortLongTermDebtTotal, last quarter) (leases 102.0m already included)
Net Debt = -234.7m USD (calculated: Debt 102.0m - CCE 336.7m)
Enterprise Value = 10.5b USD (10.7b + Debt 102.0m - CCE 336.7m)
Interest Coverage Ratio = -35.13 (Ebit TTM -169.2m / Interest Expense TTM 4.82m)
EV/FCF = 290.6x (Enterprise Value 10.5b / FCF TTM 36.0m)
FCF Yield = 0.34% (FCF TTM 36.0m / Enterprise Value 10.5b)
FCF Margin = 5.22% (FCF TTM 36.0m / Revenue TTM 690.3m)
Net Margin = -24.60% (Net Income TTM -169.8m / Revenue TTM 690.3m)
Gross Margin = 81.13% ((Revenue TTM 690.3m - Cost of Revenue TTM 130.3m) / Revenue TTM)
Gross Margin QoQ = 85.23% (prev 81.67%)
Tobins Q-Ratio = 10.69 (Enterprise Value 10.5b / Total Assets 979.5m)
Interest Expense / Debt = 4.72% (Interest Expense 4.82m / Debt 102.0m)
Taxrate = 13.05% (303k / 2.32m)
NOPAT = -147.1m (EBIT -169.2m * (1 - 13.05%)) [loss with tax shield]
Current Ratio = 4.57 (Total Current Assets 579.6m / Total Current Liabilities 126.7m)
Debt / Equity = 0.14 (Debt 102.0m / totalStockholderEquity, last quarter 717.3m)
Debt / EBITDA = 1.91 (negative EBITDA) (Net Debt -234.7m / EBITDA -122.9m)
Debt / FCF = -6.52 (Net Debt -234.7m / FCF TTM 36.0m)
Total Stockholder Equity = 681.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.16% (Net Income -169.8m / Total Assets 979.5m)
RoE = -24.91% (Net Income TTM -169.8m / Total Stockholder Equity 681.7m)
RoCE = -19.84% (EBIT -169.2m / Capital Employed (Total Assets 979.5m - Current Liab 126.7m))
RoIC = -17.98% (negative operating profit) (NOPAT -147.1m / Invested Capital 818.3m)
WACC = 8.24% (E(10.7b)/V(10.8b) * Re(8.28%) + D(102.0m)/V(10.8b) * Rd(4.72%) * (1-Tc(0.13)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.05 | Cagr: 8.71%
[DCF] Terminal Value 75.44% ; FCFF base≈36.0m ; Y1≈36.2m ; Y5≈38.3m
[DCF] Fair Price = 14.08 (EV 595.9m - Net Debt -234.7m = Equity 830.6m / Shares 59.0m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.06 | # QB: 1
Revenue Correlation: 98.88 | Revenue CAGR: 32.36% | SUE: 4.0 | # QB: 10
EPS current Quarter (2027-03-31): EPS=0.02 | Chg30d=N/A | Revisions=+44% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.30 | Chg30d=-2.37% | Revisions=+80% | GrowthEPS=+67.0% | GrowthRev=+36.3%
EPS next Year (2027-12-31): EPS=0.52 | Chg30d=+3.67% | Revisions=+50% | GrowthEPS=+275.7% | GrowthRev=+23.2%
[Analyst] Revisions Ratio: +79% (up=20, down=1)